BRPI0812250A2 - Composição farmacêutica de liberação lenta feita de micropartículas - Google Patents

Composição farmacêutica de liberação lenta feita de micropartículas

Info

Publication number
BRPI0812250A2
BRPI0812250A2 BRPI0812250-4A2A BRPI0812250A BRPI0812250A2 BR PI0812250 A2 BRPI0812250 A2 BR PI0812250A2 BR PI0812250 A BRPI0812250 A BR PI0812250A BR PI0812250 A2 BRPI0812250 A2 BR PI0812250A2
Authority
BR
Brazil
Prior art keywords
microparticles
pharmaceutical composition
slow release
release pharmaceutical
composition made
Prior art date
Application number
BRPI0812250-4A2A
Other languages
English (en)
Inventor
Bertrand Ducrey
Patrick Garrouste
Catherine Curdy
Marie-Anne Bardet
Herve Porchet
Eija Lundstrom
Frederic Heimgartner
Original Assignee
Debio Rech Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0812250(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debio Rech Pharma Sa filed Critical Debio Rech Pharma Sa
Publication of BRPI0812250A2 publication Critical patent/BRPI0812250A2/pt
Publication of BRPI0812250B1 publication Critical patent/BRPI0812250B1/pt
Publication of BRPI0812250B8 publication Critical patent/BRPI0812250B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0812250A 2007-06-06 2008-06-06 composição farmacêutica de liberação lenta de uma triptorelina agonista de lhrh feita de micropartículas e uso da mesma BRPI0812250B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07109767.9 2007-06-06
EP07109767 2007-06-06
IBPCT/IB2007/054372 2007-10-27
IB2007054372 2007-10-27
PCT/IB2008/052241 WO2008149320A2 (en) 2007-06-06 2008-06-06 Slow release pharmaceutical composition made of microparticles

Publications (3)

Publication Number Publication Date
BRPI0812250A2 true BRPI0812250A2 (pt) 2014-12-23
BRPI0812250B1 BRPI0812250B1 (pt) 2020-03-03
BRPI0812250B8 BRPI0812250B8 (pt) 2021-05-25

Family

ID=40032512

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812250A BRPI0812250B8 (pt) 2007-06-06 2008-06-06 composição farmacêutica de liberação lenta de uma triptorelina agonista de lhrh feita de micropartículas e uso da mesma

Country Status (32)

Country Link
US (4) US10166181B2 (pt)
EP (3) EP3431077A1 (pt)
JP (1) JP5419169B2 (pt)
KR (1) KR101631475B1 (pt)
CN (1) CN101677959B (pt)
AP (1) AP3000A (pt)
AU (1) AU2008259411B2 (pt)
BR (1) BRPI0812250B8 (pt)
CA (1) CA2688478C (pt)
CO (1) CO6251234A2 (pt)
CY (2) CY1118434T1 (pt)
DK (2) DK2500014T4 (pt)
EA (1) EA019284B1 (pt)
ES (2) ES2694401T5 (pt)
FI (1) FI2500014T4 (pt)
HR (2) HRP20181854T4 (pt)
HU (2) HUE031550T2 (pt)
IL (1) IL202501A (pt)
LT (2) LT2164467T (pt)
MA (1) MA31422B1 (pt)
ME (1) ME00959B (pt)
MX (1) MX2009012856A (pt)
MY (1) MY150450A (pt)
NZ (1) NZ582423A (pt)
PL (2) PL2164467T3 (pt)
PT (2) PT2164467T (pt)
RS (2) RS58248B1 (pt)
SI (2) SI2500014T2 (pt)
TN (1) TN2009000476A1 (pt)
UA (1) UA99830C2 (pt)
WO (1) WO2008149320A2 (pt)
ZA (1) ZA200907940B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5419169B2 (ja) 2007-06-06 2014-02-19 デビオファーム リサーチ アンド マニュファクチャリング ソシエテ アノニム 微小粒子で構成される徐放性医薬組成物
PT105270B (pt) 2010-08-26 2012-05-31 Domino Ind Ceramicas S A Camada de sílica com libertação lenta de fragrância, telha cerâmica e respectivo processo de produção
CN105267153B (zh) * 2015-11-27 2018-05-11 上海苏豪逸明制药有限公司 一种曲普瑞林缓释微粒及其制备方法
CN105797134B (zh) * 2016-03-29 2019-06-14 浙江圣兆药物科技股份有限公司 一种难溶亮丙瑞林缓释制剂
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
KR102402639B1 (ko) 2017-11-24 2022-05-26 삼성전자주식회사 전자 장치 및 그의 통신 방법
CN111000798B (zh) * 2019-12-26 2021-11-23 四川恒博生物科技有限公司 一种采用原位凝胶技术的犬用非手术去势注射液
IT202000017191A1 (it) 2020-07-15 2022-01-15 Xbrane Biopharma Ab Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale
AR133300A1 (es) 2023-07-20 2025-09-17 Ferring Bv Micropartículas cargadas con fármaco de liberación prolongada
TW202529795A (zh) * 2023-11-08 2025-08-01 瑞士商戴比歐醫藥國際公司 新穎組成物
CN121401211A (zh) * 2024-02-29 2026-01-27 珠海市华海康医药科技有限责任公司 一种双羟萘酸盐药物缓释微球及其制备方法
CN121818889A (zh) 2024-10-08 2026-04-10 费灵有限公司 曲普瑞林组合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3678308D1 (de) 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
CH679207A5 (pt) * 1989-07-28 1992-01-15 Debiopharm Sa
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
ATE223702T1 (de) * 1993-10-22 2002-09-15 Genentech Inc Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
MY118835A (en) 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
AU1384199A (en) * 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
TW200800298A (en) * 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
US20040170665A1 (en) 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
CA2463358C (fr) 2001-10-10 2012-03-13 Pierre Fabre Medicament Microspheres biodegradables a liberation prolongee et leur procede de preparation
MXPA05011299A (es) * 2003-04-30 2006-01-24 Debiopharm Sa Metodos y composiciones utilizando la hormona liberadora de la hormona gonadotropina.
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
FR2865938B1 (fr) * 2004-02-05 2006-06-02 Sod Conseils Rech Applic Formulation retard solide comprenant de l'acetate de triptoreline
ES2755032T3 (es) 2005-12-22 2020-04-21 Novartis Ag Formulación de liberación sostenida que comprende octreótido y dos o más polímeros de poliláctido-co-glicólido
JP5419169B2 (ja) 2007-06-06 2014-02-19 デビオファーム リサーチ アンド マニュファクチャリング ソシエテ アノニム 微小粒子で構成される徐放性医薬組成物

Also Published As

Publication number Publication date
AU2008259411B2 (en) 2013-10-17
MA31422B1 (fr) 2010-06-01
ES2694401T3 (es) 2018-12-20
RS55591B1 (sr) 2017-06-30
IL202501A (en) 2015-11-30
EP2500014A2 (en) 2012-09-19
US20230082575A1 (en) 2023-03-16
LT2164467T (lt) 2017-01-25
HUE040391T2 (hu) 2019-03-28
PL2500014T5 (pl) 2025-05-05
KR101631475B1 (ko) 2016-06-20
US20190192423A1 (en) 2019-06-27
HK1141737A1 (en) 2010-11-19
US20250205148A1 (en) 2025-06-26
WO2008149320A2 (en) 2008-12-11
US20110052717A1 (en) 2011-03-03
HRP20181854T1 (hr) 2019-02-08
SI2164467T1 (sl) 2017-05-31
CY1118434T1 (el) 2017-06-28
JP5419169B2 (ja) 2014-02-19
LT2500014T (lt) 2019-01-25
CO6251234A2 (es) 2011-02-21
CN101677959A (zh) 2010-03-24
ES2694401T5 (es) 2025-05-16
PL2500014T3 (pl) 2019-04-30
ME00959B (me) 2012-06-20
MX2009012856A (es) 2009-12-15
MY150450A (en) 2014-01-30
EP2500014B2 (en) 2025-02-19
EP2500014A3 (en) 2012-11-07
CY1120891T1 (el) 2019-12-11
AP3000A (en) 2014-10-31
AP2009005088A0 (en) 2009-12-31
PT2164467T (pt) 2017-01-13
UA99830C2 (uk) 2012-10-10
DK2500014T3 (en) 2018-12-03
WO2008149320A3 (en) 2009-02-05
DK2164467T3 (en) 2017-01-30
IL202501A0 (en) 2010-06-30
NZ582423A (en) 2011-10-28
BRPI0812250B8 (pt) 2021-05-25
RS58248B1 (sr) 2019-03-29
ZA200907940B (en) 2010-08-25
HUE031550T2 (en) 2017-07-28
CN101677959B (zh) 2014-02-26
EP2500014B1 (en) 2018-08-08
CA2688478A1 (en) 2008-12-11
EP3431077A1 (en) 2019-01-23
HRP20181854T4 (hr) 2025-05-09
EP2164467B1 (en) 2016-12-14
EA019284B1 (ru) 2014-02-28
EA200971132A1 (ru) 2010-04-30
EP2164467A2 (en) 2010-03-24
SI2500014T1 (sl) 2019-02-28
AU2008259411A1 (en) 2008-12-11
KR20100023950A (ko) 2010-03-04
BRPI0812250B1 (pt) 2020-03-03
US10166181B2 (en) 2019-01-01
PL2164467T3 (pl) 2017-07-31
CA2688478C (en) 2015-10-27
PT2500014T (pt) 2018-11-21
FI2500014T4 (fi) 2025-04-08
JP2010529106A (ja) 2010-08-26
DK2500014T4 (da) 2025-04-14
HRP20161785T1 (hr) 2017-03-10
ES2611020T3 (es) 2017-05-04
SI2500014T2 (sl) 2025-05-30
TN2009000476A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
BRPI0812250A2 (pt) Composição farmacêutica de liberação lenta feita de micropartículas
LTPA2018005I1 (lt) Farmacinė kompozicija
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
PT2435030E (pt) Composições farmacêuticas flutuantes de libertação controlada
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
BRPI0721651A2 (pt) Composição farmacêutica
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
EP2341773A4 (en) PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN
BRPI0921313A2 (pt) composição farmaucêutica
PT2209464E (pt) Composição farmacêutica antimalárica
EP2320729A4 (en) GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
EP2501225A4 (en) PHARMACEUTICAL COMPOSITION FROM MELANOCORTIN RECEPTOR LIGANDS
BRPI0912171A2 (pt) composição farmacêutica
BRPI0921301A2 (pt) composição farmacêutica
BRPI0912074A2 (pt) composto e composição farmacêutica
EP2405754A4 (en) PHARMACEUTICAL BUPRENORPHINE COMPOSITIONS WITH MODIFIED RELEASE
PT2429501T (pt) Composições de libertação imediata de fármaco
EP2488175A4 (en) PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: DEBIOPHARM RESEARCH AND MANUFACTURING SA (CH)

B25A Requested transfer of rights approved

Owner name: DEBIOPHARM INTERNATIONAL SA (CH)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF